Cannabidiol "CBD" Products Lead Industrial Hemp Sales As Scientific & Clinical Studies Underscore CBD's Potential - Company Exceeds Sales as Shipping Orders Begin

CORAL SPRINGS, Florida, September 10, 2014 /PRNewswire/ --

Marijuana & Cannabis industry experiences continued growth as emerging companies develop new cannabis opportunities as a result of recent clinical studies, reports provided on latest product developments from various sector related companies:  Flameret Inc. (OTC: FLRE), Cannabis Science Inc. (OTC: CBIS), Medical Marijuana Inc. (OTC: MJNA), Terra Tech Corp. (OTC: TRTC), American Green Inc. (OTC: ERBB) and Easton Pharmaceuticals Inc. (OTC: EAPH)

Flameret Inc. (OTC Pink: FLRE) announced today that Royal Hemp Corporation, its wholly-owned Colorado subsidiary, has begun shipping high CBD hemp oil orders. The company previously announced the launch of Cannadol™, its high CBD (cannabidiol) hemp oil. Over the first three days after the product launch was announced, the company received orders from 21 different customers. Further details regarding initial revenues will be announced in the company's financial statements that will be filed at http://www.otcmarkets.com.  Cannadol™ is a dietary supplement sold as a hemp oil rich in CBD. It consists of 200mg of cannabidiol cold pressed from industrial hemp in an oral suspension of 1 ounce of hemp oil. None of the statements regarding Cannadol™ or the potential therapeutic benefits of cannabidiol have been evaluated by the FDA.

To read the full press release, please click here: http://www.financialnewsmedia.com/profiles/flre.html

Scientific and clinical studies continue to underscore CBD's potential as a possible treatment for a wide range of conditions, including rheumatoid arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, antibiotic-resistant infections, epilepsy, and other neurological disorders. CBD has demonstrated neuroprotective and neurogenic capabilities, and its anti-cancer properties are currently being investigated at several academic research centers in the United States and elsewhere.  John Meredith, Chief Executive Officer of Flameret, Inc. remarked, "The launch of Cannadol™ and the response from consumers has far surpassed our internal expectations. We expect to deliver more good news to the investment public within a week."

Cannabis Science Inc. (OTCQB: CBIS) a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to provide a guidance report on its current pre-clinical drug development programs underway, beginning with the scientific cannabis cultivation programs in Europe and North America, testing multiple cannabis strains for multiple critical ailments. Mr. Mario S. Lap, Director and President of European Operations, stated, " The Company's efforts in Spain compliment Cannabis Science's plans in Canada and the Company's current, pre-clinical collaboration with the Institute for Research, Hospitalization and Health Care on Ageing (INRCA) in Italy, where the Company is testing toxicity and efficacy of cannabinoid formulations for neurobehavioral diseases including sleep disorders."

Medical Marijuana Inc. (OTC Pink: MJNA) announce that one of its investment portfolio companies, KannaLife Sciences, Inc. ("KannaLife"), is the subject of this tremendous amount of mainstream news coverage. MJNA directly owns 16.70% of KannaLife's capital stock.  KannaLife co-founder Thoma Kikis stated in a recent interview, "On the FDA drug pipeline, we are focused on treating diseases that affect the brain." Kikis went on to explain that "CTE is a concussion-induced disease with long-term effects mostly suffered by football, hockey, soccer players and boxers." CTE is defined by Boston University as: "A progressive degenerative disease of the brain found in athletes (and others) with a history of repetitive brain trauma, including symptomatic concussions as well as asymptomatic subconcussive hits to the head." KannaLife is leading the industry by tackling major issues that plague professional sports and other athletes including the NFL's mission to protect former and current players from CTE.

Terra Tech Corp. (OTCQB: TRTC) Derek Peterson, CEO of Terra Tech, called in to SmallCapVoice.com to address the recent financial results and the incredible distribution growth of Edible Garden this summer. Peterson also went over the core focuses for TRTC in remainder of 2014 and early 2015. "We are happy where things sit right now. We're happy with the core base we have built for the Company, but again we are working to be leaner, develop significant opportunities, and look for accretive transactions to use the war chest that we have created for purposes of building up the Company," stated Peterson. The full interview can be heard at http://www.globenewswire.com/newsroom/ctr?d=10097510&l=1&u=http%3A%2F%2Fsmallcapvoice.com%2Fblog%2F9-4-14-smallcapvoice-interview-with-terra-tech-corp-trtc

American Green Inc. (OTC Pink: ERBB) recently announced that it will begin the deployment of the latest version of its ZaZZZ machine in October to several dispensaries, including its first foray into a retail setting in Denver at the Ballpark Holistic Dispensary as well as several other medicinal dispensaries in multiple states. While providing the same functionality, the machines are based on the recently secured patents of Robert Tomassi, have a new user interface and technological enhancements designed to work with multiple manufactures, and are easily integrated with various inventory control companies. In addition they will carry a proprietary line of CBD products designed around pain relief and promoted by former NBA player Rex Chapman, a member of the company's advisory board. American Green is developing a new remote-access API to integrate with the ZaZZZ network. This API is being designed to work within the boundaries of the patents and to provide a unified interface for all future consumer-facing sales services, including direct product vending, mobile apps, and more.

Easton Pharmaceuticals Inc. (OTC Pink: EAPH) a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, recently announced a financing update, providing due diligence documents towards financing from a Toronto, Canada, based brokerage firm. Easton Pharmaceuticals has over the past 12 months been financed from accredited investors through regulation D offerings. These offerings were completed in April of this year where $1 Million was raised, but the offerings are not expected to be utilized again. Although the Company has received other offers for financing through various other avenues including the submission of a Reg. A filing with the Securities and Exchange Commission and investment(s) from private sources, the Company has also been diligently searching to have its financing secured through more traditional value added sources and means such as private placements through institutions. 

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services.  If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/.  Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup. 

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG has been compensated one thousand six hundred dollars for news coverage of the current press release issued by Flameret, Inc. by a non-affiliated third party.

FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.  

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company:  FN Media Group, LLC
Contact email:  [email protected]
U.S. Phone: +1-954-345-0611
URL: http://www.financialnewsmedia.com

SOURCE FN Media Group LLC